SCHEMBL6796519

SCHEMBL6796519

CCNC(=O)Nc1ccc(Oc2ccnc3cc(OC)c(C(N)=O)cc23)cc1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.62
PDGFRA P16234 7/20 0.62
AURKB Q96GD4 7/20 0.62
RET P07949 7/20 0.62
KIT P10721 4/20 0.62
PDGFRB P09619 3/20 0.62
FGFR1 P11362 3/20 0.62
FLT1 P17948 3/20 0.62
FLT4 P35916 3/20 0.62
ABL1 P00519 3/20 0.62
FGFR2 P21802 2/20 0.62
RIPK2 O43353 2/20 0.62
STK10 O94804 2/20 0.62
BCR P11274 2/20 0.62
SLC6A3 Q01959 2/20 0.62
DDR1 Q08345 2/20 0.62
MAP4K2 Q12851 2/20 0.62
PTK6 Q13882 2/20 0.62
DDR2 Q16832 2/20 0.62
RIPK3 Q9Y572 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627611 0.92 KDR (0.61) KDRPDGFRAAURKBRETKIT
SCHEMBL14540501 0.92 KDR (0.54) KDRPDGFRAAURKBRETKIT
SCHEMBL12673919 0.90 KDR (0.59) KDRPDGFRAAURKBRETKIT
SCHEMBL863736 0.90 KDR (0.76) KDRPDGFRAAURKBRETKIT
SCHEMBL1249688 0.90 KDR (0.66) KDRPDGFRAAURKBRETKIT
SCHEMBL31055824 0.90 KDR (0.76) KDRPDGFRAAURKBRETKIT
SCHEMBL6798959 0.90 KDR (0.65) KDRPDGFRAAURKBRETKIT
SCHEMBL12503783 0.90 KDR (0.65) KDRPDGFRAAURKBRETKIT
SCHEMBL1890996 0.90 KDR (0.60) KDRPDGFRAAURKBRETKIT
SCHEMBL12499932 0.88 KDR (0.59) KDRPDGFRAAURKBRETKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372981-B2 Nitrogen-containing aromatic derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-02-12 US disclosed
US-7973160-B2 Nitrogen-containing aromatic derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-07-05 US disclosed
US-7973160-B2 Nitrogen-containing aromatic derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-07-05 US disclosed
US-20110118470-A1 NITROGEN-CONTAINING AROMATIC DERIVATIVES FUNAHASHI YASUHIRO 2011-05-19 US disclosed
US-20100197911-A1 Nitrogen-Containing Aromatic Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-05 US disclosed
US-20100197911-A1 Nitrogen-Containing Aromatic Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-05 US disclosed
US-7612092-B2 Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-11-03 US disclosed
US-7612092-B2 Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-11-03 US disclosed
US-7253286-B2 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI CO., LTD (JP) 2007-08-07 US disclosed
US-7253286-B2 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI CO., LTD (JP) 2007-08-07 US disclosed
US-20040053908-A1 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197911-A1 Nitrogen-Containing Aromatic Derivatives GNG2, GCG, FRG1 KDR 2687/4885PDGFRA 3131/4885AURKB 1909/4885
US-20040053908-A1 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective VEGFA, UACA, UTS2R KDR 22/4885PDGFRA 1572/4885AURKB 2738/4885
US-20110118470-A1 NITROGEN-CONTAINING AROMATIC DERIVATIVES GNG2, GCG, FRG1 KDR 2782/4885PDGFRA 3135/4885AURKB 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.